AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Monday the grant by the US Food and Drug Administration (FDA) of Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs.
Reportedly, Saracatinib is an inhibitor of src kinase, which regulates broad cell functions, including cell growth and cell differentiation. Saracatinib has completed phase I development.
The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.
According to the company, saracatinib is a small molecule, highly-potent and selective inhibitor of src tyrosine kinase. This potential new medicine was discovered by AstraZeneca and has previously been in clinical development in oncology. Phase II trials for saracatinib in IPF have not yet commenced.
AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy